98 related articles for article (PubMed ID: 22709867)
1. Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells.
Valente S; Lepore I; Dell'Aversana C; Tardugno M; Castellano S; Sbardella G; Tomassi S; Di Maro S; Novellino E; Di Santo R; Costi R; Altucci L; Mai A
Biochimie; 2012 Nov; 94(11):2308-13. PubMed ID: 22709867
[TBL] [Abstract][Full Text] [Related]
2. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors.
Woo J; Kim HY; Byun BJ; Chae CH; Lee JY; Ryu SY; Park WK; Cho H; Choi G
Bioorg Med Chem Lett; 2014 Jun; 24(11):2486-92. PubMed ID: 24767850
[TBL] [Abstract][Full Text] [Related]
3. New lysine methyltransferase drug targets in cancer.
Wagner T; Jung M
Nat Biotechnol; 2012 Jul; 30(7):622-3. PubMed ID: 22781684
[No Abstract] [Full Text] [Related]
4. Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2.
Dudakovic A; Camilleri ET; Xu F; Riester SM; McGee-Lawrence ME; Bradley EW; Paradise CR; Lewallen EA; Thaler R; Deyle DR; Larson AN; Lewallen DG; Dietz AB; Stein GS; Montecino MA; Westendorf JJ; van Wijnen AJ
J Biol Chem; 2015 Nov; 290(46):27604-17. PubMed ID: 26424790
[TBL] [Abstract][Full Text] [Related]
5. Quantification of histone H3 Lys27 trimethylation (H3K27me3) by high-throughput microscopy enables cellular large-scale screening for small-molecule EZH2 inhibitors.
Luense S; Denner P; Fernández-Montalván A; Hartung I; Husemann M; Stresemann C; Prechtl S
J Biomol Screen; 2015 Feb; 20(2):190-201. PubMed ID: 25409661
[TBL] [Abstract][Full Text] [Related]
6. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
Konze KD; Ma A; Li F; Barsyte-Lovejoy D; Parton T; Macnevin CJ; Liu F; Gao C; Huang XP; Kuznetsova E; Rougie M; Jiang A; Pattenden SG; Norris JL; James LI; Roth BL; Brown PJ; Frye SV; Arrowsmith CH; Hahn KM; Wang GG; Vedadi M; Jin J
ACS Chem Biol; 2013; 8(6):1324-34. PubMed ID: 23614352
[TBL] [Abstract][Full Text] [Related]
7. Disturbing the histone code in leukemia: translocations and mutations affecting histone methyl transferases.
Chopra M; Bohlander SK
Cancer Genet; 2015 May; 208(5):192-205. PubMed ID: 25592767
[TBL] [Abstract][Full Text] [Related]
8. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
Knutson SK; Wigle TJ; Warholic NM; Sneeringer CJ; Allain CJ; Klaus CR; Sacks JD; Raimondi A; Majer CR; Song J; Scott MP; Jin L; Smith JJ; Olhava EJ; Chesworth R; Moyer MP; Richon VM; Copeland RA; Keilhack H; Pollock RM; Kuntz KW
Nat Chem Biol; 2012 Nov; 8(11):890-6. PubMed ID: 23023262
[TBL] [Abstract][Full Text] [Related]
9. Multiple Histone Lysine Methyltransferases Are Required for the Establishment and Maintenance of HIV-1 Latency.
Nguyen K; Das B; Dobrowolski C; Karn J
mBio; 2017 Feb; 8(1):. PubMed ID: 28246360
[TBL] [Abstract][Full Text] [Related]
10. De novo peptide design and experimental validation of histone methyltransferase inhibitors.
Smadbeck J; Peterson MB; Zee BM; Garapaty S; Mago A; Lee C; Giannis A; Trojer P; Garcia BA; Floudas CA
PLoS One; 2014; 9(2):e90095. PubMed ID: 24587223
[TBL] [Abstract][Full Text] [Related]
11. Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.
Chen J; Li J; Han Q; Sun Z; Wang J; Wang S; Zhao RC
Exp Biol Med (Maywood); 2012 Sep; 237(9):1110-6. PubMed ID: 22956625
[TBL] [Abstract][Full Text] [Related]
12. The Importance of Being Me: Magic Methyls, Methyltransferase Inhibitors, and the Discovery of Tazemetostat.
Kuntz KW; Campbell JE; Keilhack H; Pollock RM; Knutson SK; Porter-Scott M; Richon VM; Sneeringer CJ; Wigle TJ; Allain CJ; Majer CR; Moyer MP; Copeland RA; Chesworth R
J Med Chem; 2016 Feb; 59(4):1556-64. PubMed ID: 26769278
[TBL] [Abstract][Full Text] [Related]
13. S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.
Liu TP; Lo HL; Wei LS; Hsiao HH; Yang PM
Anticancer Drugs; 2015 Feb; 26(2):139-47. PubMed ID: 25203626
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in EZH2-based dual inhibitors in the treatment of cancers.
Yang X; Xu L; Yang L
Eur J Med Chem; 2023 Aug; 256():115461. PubMed ID: 37156182
[TBL] [Abstract][Full Text] [Related]
15. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer.
Kim W; Bird GH; Neff T; Guo G; Kerenyi MA; Walensky LD; Orkin SH
Nat Chem Biol; 2013 Oct; 9(10):643-50. PubMed ID: 23974116
[TBL] [Abstract][Full Text] [Related]
16. Fluorescence-based methods for screening writers and readers of histone methyl marks.
Allali-Hassani A; Wasney GA; Siarheyeva A; Hajian T; Arrowsmith CH; Vedadi M
J Biomol Screen; 2012 Jan; 17(1):71-84. PubMed ID: 21972038
[TBL] [Abstract][Full Text] [Related]
17. Loss of BAP1 function leads to EZH2-dependent transformation.
LaFave LM; Béguelin W; Koche R; Teater M; Spitzer B; Chramiec A; Papalexi E; Keller MD; Hricik T; Konstantinoff K; Micol JB; Durham B; Knutson SK; Campbell JE; Blum G; Shi X; Doud EH; Krivtsov AV; Chung YR; Khodos I; de Stanchina E; Ouerfelli O; Adusumilli PS; Thomas PM; Kelleher NL; Luo M; Keilhack H; Abdel-Wahab O; Melnick A; Armstrong SA; Levine RL
Nat Med; 2015 Nov; 21(11):1344-9. PubMed ID: 26437366
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.
Dreger H; Ludwig A; Weller A; Stangl V; Baumann G; Meiners S; Stangl K
Hypertension; 2012 Nov; 60(5):1176-83. PubMed ID: 22966008
[TBL] [Abstract][Full Text] [Related]
19. Targeting histone methyltransferase EZH2 as cancer treatment.
Kondo Y
J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic reprogramming in solid tumors: therapeutic implications of EZH2 gain-of-function mutations.
Barsotti AM; Ryskin M; Rollins RA
Epigenomics; 2015 Aug; 7(5):687-90. PubMed ID: 26317265
[No Abstract] [Full Text] [Related]
[Next] [New Search]
